Table 2.

Association between markers and cognitive groups

Measure	Wald test	CIND versus Normal	Dementia versus CIND	Dementia versus Normal
	P-value	OR (95% CI)	OR (95% CI)	OR (95% CI)
		P-value	P-value	P-value
Synaptophysin	0.002	5.59 (0.20–159.45)	0.01 (<0.01–0.11)	0.03 (<0.01–0.59)
		0.314	0.001	0.021
SV2	0.017	2.85 (0.10–84.75)	0.02 (<0.01–0.35)	0.05 (<0.01–0.93)
		0.546	0.008	0.045
VGLUT1	0.099	0.04 (<0.01–2.41)	0.56 (0.02–18.84)	0.02 (<0.01–0.76)
		0.124	0.747	0.034
Braak stage	0.001	1.06 (0.75–1.50)	1.52 (1.07–2.16)	1.68 (1.24–2.30)
		0.740	0.020	0.001
Thal phase	0.037	1.37 (0.89–2.11)	1.20 (0.84–1.71)	1.64 (1.12–2.38)
		0.158	0.318	0.011
Hippocampal sclerosis	<0.001	0.94 (0.36–2.49)	3.32 (1.56–7.05)	3.13 (1.48–6.64)
		0.906	0.002	0.003
Cerebrovascular disease	0.004	0.94 (0.35–2.55)	2.99 (1.31–6.83)	2.81 (1.29–6.13)
		0.900	0.009	0.009
TDP-43	0.008	0.90 (0.20–4.05)	4.32 (1.34–13.95)	3.89 (1.23–12.36)
		0.893	0.014	0.021

Odds ratios and 95% CIs were generated from multinomial logistic regression models where the dependent (outcome) variable was cognitive group (normal, CIND, or dementia) and the independent variables were the neuropathological markers as continuous variables, except TARDBP which was a binary variable. P-values <0.05 are in bold. Age at death and gender were included as covariates and each neuropathological measure was analysed in a separate model. The overall P-value corresponds to the type 3 analyses and tests whether the neuropathological marker (independent variable) is significantly associated with the cognitive group (outcome variable). Odds ratios are per unit. n for each group = 149 (synaptophysin), 151 (SV2), 152 (VGLUT1), 157 (Braak stage), 150 (Thal phase), 155 (hippocampal sclerosis, 108 (cerebrovascular disease) and 146 (TARDBP).